June 5, 2019
Pillet S et al. PLoS One 2019;14(6):e0216533.
Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate – Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults
You might also be interested by
Scientific Publications
Seroconversion stages COVID19 into distinct pathophysiological states
December 7, 2020
Immune Monitoring
More infoPosters
Monitoring MDSC – A Hurdle to Immune Checkpoints Inhibitors
November 9, 2020
Flow Cytometry
More infoPosters
Multiple Myeloma Flow Cytometry Panel Validated for Clinical Monitoring of Patients
November 9, 2020
Flow Cytometry
More infoWebinars
ICS and ELISpot for The Study of Cell Response: Choosing the Optimal Method in Immuno-Oncology or COVID-19 Vaccination Trials
October 29, 2020
Immune Monitoring
More info